Clyde Biosciences Limited is a registered limited company operating in the field of biotechnology research and development, specializing in cell biology and drug development. Established in 2012, the company focuses on providing a comprehensive cell platform solution centered around cardiomyocyte assays. Clyde Biosciences’ core competency lies in the development and provision of a highly validated CellOPTIQ platform, designed to facilitate rigorous safety and efficacy testing of novel therapeutics. This platform offers a suite of tools and methodologies specifically tailored for investigating cellular responses to drug candidates, particularly concerning cardiomyocyte behavior. The company’s primary service offering is the creation and delivery of optimized cell assays, supporting early-stage drug development and preclinical research. Clyde Biosciences is dedicated to accelerating the drug development process through the provision of reliable and validated assays. As an official member of the CiPA (Clinical Investigational Pharmaceutical Association), Clyde Biosciences is committed to adhering to industry best practices and regulatory standards. The company operates internationally, with a growing presence in strategic markets. Clyde Biosciences Limited’s size is estimated to be a small to medium-sized enterprise, with a focus on skilled workforce development and a strong commitment to innovation within the biotechnology sector.

Clyde Biosciences Limited is a registered limited company operating in the field of biotechnology research and development, specializing in cell biology and drug development. Established in 2012, the company focuses on providing a comprehensive cell platform solution centered around cardiomyocyte assays. Clyde Biosciences’ core competency lies in the development and provision of a highly validated CellOPTIQ platform, designed to facilitate rigorous safety and efficacy testing of novel therapeutics. This platform offers a suite of tools and methodologies specifically tailored for investigating cellular responses to drug candidates, particularly concerning cardiomyocyte behavior. The company’s primary service offering is the creation and delivery of optimized cell assays, supporting early-stage drug development and preclinical research. Clyde Biosciences is dedicated to accelerating the drug development process through the provision of reliable and validated assays. As an official member of the CiPA (Clinical Investigational Pharmaceutical Association), Clyde Biosciences is committed to adhering to industry best practices and regulatory standards. The company operates internationally, with a growing presence in strategic markets. Clyde Biosciences Limited’s size is estimated to be a small to medium-sized enterprise, with a focus on skilled workforce development and a strong commitment to innovation within the biotechnology sector.